Navigation Links
Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
Date:7/7/2009

products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1032 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
2. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
3. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
4. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
5. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
6. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
7. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
8. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
9. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
10. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
11. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... (OTCBB: GNLK, "the Company," or "GeneLink"), a leading consumer ... year ended December 31, 2010. Financial Highlights: ... 2009 to $4,997,367 in 2010; Annual net sales ... 2009; Operating losses in 2010 decreased to $2,169,898, a ...
... SEATTLE, April 4, 2011 Omeros Corporation (NASDAQ: ... developing and commercializing products focused on inflammation, bleeding and ... Gregory A. Demopulos, M.D., chairman and chief executive officer, ... Healthcare Conference taking place in New York City this ...
... proteins, polymers, minerals, and engineered materials will be published ... Nature Materials . The discovery by two Penn State ... the structure of materials, which the researchers say greatly ... desired properties. The research is expected to have broad ...
Cached Biology Technology:GeneLink Reports 2010 Results 2Search for advanced materials aided by discovery of hidden symmetries in nature 2Search for advanced materials aided by discovery of hidden symmetries in nature 3
(Date:4/15/2014)... (KNAW) has announced the names of five internationally renowned ... million US dollars prize money in total). The laureates ... science. , This year marks the 50th anniversary of ... Erwin Chargaff in 1964. , KNAW juries have ... , Christopher M. Dobson, John Humphrey Plummer ...
(Date:4/15/2014)... 2050, deforestation could cause temperatures in the Congo ... would intensify warming caused by greenhouse gases by ... the University of Leuven, Belgium. , Explosive population ... destruction of tropical rainforests in Central Africa. A ... examined how these practices will affect longer-term temperatures ...
(Date:4/15/2014)... cuttlefish, squid and octopus has uncovered details of ... they may help in investigating populations of their ... 10 new parasite species− dicyemid mesozoans −, which ... and octopus). They are the very first ... , "Although dicyemid parasites have been studied ...
Breaking Biology News(10 mins):Five scientists awarded prestigious Heineken Prizes 2Study: Deforestation could intensify climate change in Congo Basin by half 2Bizarre parasite may provide cuttlefish clues 2
... This press release is available in Spanish . ... radiotherapy to the lymph nodes located behind the breast bone ... breast conserving surgery, a radiation oncologist will tell delegates at ... March). Women at a high risk of developing breast cancer ...
... may shed light on how climate over millions of years ... that will discuss the findings and recommendations of the National ... Several members of the committee that wrote the report will ... next 10 to 20 years and answer audience questions. ...
... (LF) and the Nanyang Technological University (NTU) today announced ... to poor communities in the region with fresh funds, ... programme. The Lien Foundation is injecting a ... (Endeavour). Started in 2006, the Endeavour seeks to improve ...
Cached Biology News:Specific lymph node radiotherapy is well-tolerated after surgery in early breast cancer patients 2NTU and Lien Foundation launch second second wave of Environmental Endeavor 2NTU and Lien Foundation launch second second wave of Environmental Endeavor 3
... Combining linear motor and ballscrew ... pre-engineered Cartesian solutions that include ... management, and motors., , ... Pass through high-flex cabling for ...
UGT1A6 (D-20)...
... T Squareds patented high efficiency dynamic valve ... With the most compact, lightweight package in ... use in portable air and gas applications., ... high efficiency. , Includes DC Motor. ...
... designed for moving loads quickly and accurately. ... output while limiting overall size. The P5S-P ... ball bearings guided on two rails., ... provide energy absorption and controlled deceleration , ...
Biology Products: